Additionally, intraperitoneal administration of GLP-1 at supraphysiological doses elicited an anti-adipogenic effect in rats (72), making GLP-1 a potential target for obesity treatment. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.